US Brand Name(s) for Ibrutinib: Imbruvica
Use in Cancer Treatment
Experts have authorized Ibrutinib to treat the following conditions:
- Adults with chronic lymphocytic leukemia and small lymphocytic lymphoma. People can use it alone or in combination with other medications.
- Adults with mantle cell lymphoma who have had at least one prior therapy.
- Lymphoma of the marginal zone. It’s given to individuals who’ve had at least one prior CD20-targeted treatment.
- Waldenström macroglobulinemia (a form of non-Hodgkin lymphoma) is a type of non-Hodgkin lymphoma that affects adults.
The FDA’s Accelerated Approval Program has authorized this usage. Confirmatory trials must prove that ibrutinib has a clinical benefit in these individuals as a condition of approval.
Ibrutinib is also being researched for use in the treatment of various cancers.
Dor detailed definition Definition from the NCI Drug Dictionary
Ibrutinib – Information on MedlinePlus – A summary of key information regarding this medicine in layman’s terms, which may contain the following:
Cautions about this medicine; what are its uses and how to use it; what you should tell your doctor before taking it; things you should know about it before using it; other drugs that might interact with it; and possible negative effects.
Experts frequently investigate drugs to see whether they can treat or prevent conditions other than those with authorization. This patient information leaflet only covers authorized uses of the medications. However, much of the material might also apply to authorized uses under investigation.
